Physician profile

William W Hooper

Pulmonary Disease · Encinitas, CA

NPI 1720052988

$6,963.08

in general payments reported to CMS, 2019-2025

43 companies · $184 in 2025

The $184 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,376.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $1,310.42 2019-2025 Ofev, Spiriva Respimat, Stiolto Respimat
Glaxosmithkline, LLC. $1,120.26 2019-2024 Trelegy Ellipta, Nucala, Arexvy
Astrazeneca Pharmaceuticals LP $637.67 2019-2023 Tezspire, Tagrisso, Fasenra
Philips North America LLC $431.39 2019-2023
Genzyme Corporation $333.10 2020-2025
Actelion Pharmaceuticals US, INC. $301.41 2019-2024 Opsumit, Uptravi
Grifols USA, LLC $237.84 2019-2025 Prolastin-C Liquid
Advanced Respiratory, INC $214.31 2019-2021
Mylan Specialty L.P. $191.68 2019-2024 Yupelri
Allergan, INC. $143.18 2019
Regeneron Healthcare Solutions, INC. $137.44 2019-2024 Dupixent
Sunovion Pharmaceuticals INC. $125.95 2019-2020
Janssen Scientific Affairs, LLC $124.91 2021
Merck Sharp & Dohme LLC $121.72 2019-2024 Winrevair
Genentech USA, INC. $118.28 2019-2020
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $117.10 2022-2025 Tezspire
Ortho Dermatologics, A Division of Bausch Health US, LLC $100.00 2019
Mallinckrodt Hospital Products INC. $96.76 2021-2023 Acthar
Celgene Corporation $92.05 2019
United Therapeutics Corporation $89.30 2019-2023 Tyvaso
E.R. Squibb & Sons, L.L.C. $86.82 2019-2021
Takeda Pharmaceuticals U.S.A., INC. $75.74 2021-2022
Insmed, INC. $70.11 2019-2020
Paratek Pharmaceuticals, INC. $62.45 2021
Pinnacle Biologics, INC $55.00 2021
Sobi, INC $54.97 2021-2022
Gilead Sciences, INC. $49.02 2019
Novartis Pharmaceuticals Corporation $46.72 2019
Circassia INC. $46.43 2019
Ani Pharmaceuticals, INC. $45.68 2024-2025 Purified Cortrophin Gel
Otsuka America Pharmaceutical, INC. $45.46 2019
Pfizer INC. $43.53 2021-2023
Baxter Healthcare $35.87 2022
Vapotherm INC $33.13 2022
Abbvie INC. $21.39 2024
Inogen, INC. $20.27 2019
Pulmonx Corporation $20.09 2019
Janssen Biotech, INC. $19.55 2023 Erleada
Verona Pharma, INC. $19.42 2025 Ohtuvayre
Shire North American Group INC $17.29 2019
Itamar Medical INC $16.63 2022
Jazz Pharmaceuticals INC. $16.52 2019
Janssen Pharmaceuticals, INC $16.22 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

William W Hooper

$6,963.08

in general payments reported 2019-2025

Years
2019-2025
Top company
Boehringer Ingelheim Pharmaceuticals, INC.
Context
The $184 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/78056/william-w-hooper

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.